Hematology - European Medical Journal

Continue

Hematology

Filter
3 Jul 2015

Ongoing studies by the German CLL study group (GCLLSG)

At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses…
3 Jul 2015

HELIOS: Phase 3 trial of ibrutinib in previously treated CLL/SLL

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the…
26 Jun 2015

ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain…
26 Jun 2015

Results of the phase 4 EXELS study of high-risk patients with essential thrombocythemia

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust…
26 Jun 2015

Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…
26 Jun 2015

The crucial roles of GFI1B in platelet development

The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…
26 Jun 2015

Pacritinib therapy led to symptom improvement in myelofibrosis

The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…
26 Jun 2015

Treatment and outcome of CML patients from the EUTOS population-based registry

The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).